Literature DB >> 32011726

Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm-associated venous thromboembolism in a large tertiary centre in the UK.

Natalia Curto-Garcia1, Andrew J Doyle1, Karen A Breen1, Donal P McLornan1, Deepti H Radia1, Beverley J Hunt1, Gavin Ling1, Claire N Harrison1.   

Abstract

Entities:  

Keywords:  direct oral anticoagulant therapy; myeloproliferative disorder; thrombosis (venous)

Year:  2020        PMID： 32011726     DOI： 10.1111/bjh.16485

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  7 in total

1.  A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms.

Authors:  Eva N Hamulyák; Joost G Daams; Frank W G Leebeek; Bart J Biemond; Peter A W Te Boekhorst; Saskia Middeldorp; Mandy N Lauw
Journal:  Blood Adv       Date:  2021-01-12

2.  Approach to Cancer-Associated Thrombosis: Challenging Situations and Knowledge Gaps.

Authors:  Tzu-Fei Wang; Henny H Billett; Jean M Connors; Gerald A Soff
Journal:  Oncologist       Date:  2020-12-04

Review 3.  Evidence-Based Minireview: Are DOACs an alternative to vitamin K antagonists for treatment of venous thromboembolism in patients with MPN?

Authors:  Francesca Schieppati; Anna Falanga
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

4.  Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients.

Authors:  Tiziano Barbui; Valerio De Stefano; Alessandra Carobbio; Alessandra Iurlo; Alberto Alvarez-Larran; Beatriz Cuevas; Francisca Ferrer Marín; Alessandro M Vannucchi; Francesca Palandri; Claire Harrison; Hassan Sibai; Martin Griesshammer; Massimiliano Bonifacio; Elena M Elli; Chiara Trotti; Steffen Koschmieder; Giuseppe Carli; Giulia Benevolo; Jean-Christophe Ianotto; Swati Goel; Anna Falanga; Silvia Betti; Daniele Cattaneo; Eduardo Arellano-Rodrigo; Lara Mannelli; Nicola Vianelli; Andrew Doyle; Vikas Gupta; Kai Wille; Douglas Tremblay; John Mascarenhas
Journal:  Leukemia       Date:  2021-05-19       Impact factor: 11.528

Review 5.  Polycythemia vera: historical oversights, diagnostic details, and therapeutic views.

Authors:  Ayalew Tefferi; Alessandro M Vannucchi; Tiziano Barbui
Journal:  Leukemia       Date:  2021-09-03       Impact factor: 11.528

6.  Thrombosis in myeloproliferative neoplasms: Treatment outcomes of direct oral anticoagulants and vitamin K antagonists.

Authors:  Kateryna Fedorov; Swati Goel; Margarita Kushnir; Henny H Billett
Journal:  Res Pract Thromb Haemost       Date:  2021-09-14

7.  Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms.

Authors:  Karlo Huenerbein; Parvis Sadjadian; Tatjana Becker; Vera Kolatzki; Eva Deventer; Carina Engelhardt; Martin Griesshammer; Kai Wille
Journal:  Ann Hematol       Date:  2020-11-20       Impact factor: 3.673
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.